Skip to main content

Bodmer Mark's Form 4 filing

Evelo Biosciences, Inc. (EVLO) · filed Jun 12, 2023

Accession no.
0001694665-23-000080
Filed
Jun 12, 2023, 4:01 PM ET
Trade date
May 23, 2023
Filing delay
20 daysLate
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction. Open-market sales total $3.20K. It was filed 20 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bodmer MarkCIK 0001738885Officer (CSO, President of R&D)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 23, 2023Common StockSSaleDisposed−22,571$0.1418F2−$3,200.57262,557Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $0.14 to $0.15, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24: Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)